ArticleJournal of clinical apheresis2026
Bleeding Risk Is Not Increased When Initiating Therapeutic Plasma Exchange in Adults Using Exclusively Albumin Replacement Fluid 2 Days After Percutaneous Kidney Biopsy.
Article in Journal of clinical apheresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The practice of selecting replacement fluid for therapeutic plasma exchange (TPE) after percutaneous kidney biopsy is variable and often depends on the number of days after biopsy that the apheresis treatment plan is initiated. It has been previously reported that most centers utilize plasma for at least part of replacement fluid for TPE after kidney biopsy, and quite often for many days. In this retrospective study, 100 consecutive patients who underwent percutaneous kidney biopsy and had TPE initiated 2 days after biopsy were analyzed. Half of these patients had exclusively albumin replacement fluid, and the other half had replacement fluid with both albumin and plasma. Rates for bleeding at the kidney biopsy site were identical and occurred in 1 patient (2%) in each cohort. Future studies assessing bleeding risk in this patient population receiving TPE should concentrate on the duration within 1 day after percutaneous kidney biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.